![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SPRAVATO® (esketamine) CIII nasal spray is a nonselective, noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate receptor.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Ketamine Wellness Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Ketamine treatments have successfully repaired and improved these connections while also building new, healthy ones. PTSD damage can reappear over time if the treatment is stopped and no other support strategies are put in place.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ketamine Wellness Centers
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 14, 2021